ストックスクリーナーアプリを入手
13.36
1.46%
-0.265
前日終値:
$13.62
開ける：
$13.55
24時間の取引高:
210.90K
Relative Volume:
0.21
時価総額：
$1.37B
収益：
-
当期純損益:
$-167.48M
株価収益率:
-5.8065
EPS:
-2.3
ネットキャッシュフロー:
$-197.47M
1週間 パフォーマンス:
-6.28%
1か月 パフォーマンス:
-10.11%
6か月 パフォーマンス:
-9.26%
1年 パフォーマンス:
+12.59%
1日の値動き範囲:
$13.33
$13.63
1週間の範囲:
$12.86
$14.35
52週間の値動き範囲:
$11.30
$18.07
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
名前
Day One Biopharmaceuticals Inc
セクター
電話
650 484-0899
住所
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
DAWN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| DAWN | 13.34 | 1.37B | 0 | -167.48M | -197.47M | -2.30 |
| VRTX | 446.37 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.39 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.20 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.97 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.80 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-09 | 繰り返されました | Needham | Buy |
| 2024-08-01 | アップグレード | BofA Securities | Underperform → Buy |
| 2024-04-24 | 繰り返されました | Needham | Buy |
| 2023-04-25 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-02-08 | 開始されました | CapitalOne | Overweight |
| 2023-02-03 | 開始されました | Oppenheimer | Perform |
| 2022-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-12-05 | 開始されました | Goldman | Buy |
| 2022-12-01 | 開始されました | BofA Securities | Buy |
すべてを表示
Day One Biopharmaceuticals Inc (DAWN) 最新ニュース
Day One Biopharmaceuticals announces R&D leadership change - Investing.com India
Day One Biopharmaceuticals announces R&D leadership change By Investing.com - Investing.com UK
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development - GlobeNewswire
Day One Biopharmaceuticals, Inc. Announces the Retirement of Samuel Blackman as Co-Founder and Head of Research & Development, Effective at the End of 2024 - Marketscreener.com
Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? - MSN
Day one Biopharmaceuticals COO sells shares worth $34,372 By Investing.com - Investing.com South Africa
Day One Biopharmaceuticals CEO sells $139,420 in stock - Investing.com
Day one Biopharmaceuticals COO sells shares worth $34,372 - Investing.com
Day One Biopharmaceuticals CEO sells $139,420 in stock By Investing.com - Investing.com UK
First Turn Management LLC Invests $13.20 Million in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Sees Large Increase in Short Interest - MarketBeat
First Week of July 2025 Options Trading For Day One Biopharmaceuticals (DAWN) - Nasdaq
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Day One Biopharmaceuticals to Present at Piper Sandler Healthcare Conference | DAWN Stock News - StockTitan
59,259 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by GSA Capital Partners LLP - MarketBeat
(DAWN) Trading Advice - Stock Traders Daily
TimesSquare Capital Management LLC Has $25.46 Million Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $180,257.35 in Stock - MarketBeat
FMR LLC Bolsters Position in Day One Biopharmaceuticals Inc - GuruFocus.com
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
Day One Biopharmaceuticals (NASDAQ:DAWN) Upgraded at TD Cowen - MarketBeat
Day one biopharmaceuticals head of R&D sells $8,010 in stock By Investing.com - Investing.com Canada
Day one biopharmaceuticals head of R&D sells $8,010 in stock - Investing.com
Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically - Simply Wall St
Bullish: Analysts Just Made A Huge Upgrade To Their Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Forecasts - Yahoo Finance
Equities Analysts Issue Forecasts for DAWN Q1 Earnings - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth - Yahoo Finance
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2024 Earnings Call Transcript - Insider Monkey
Day One Biopharmaceuticals’ Revenue at Risk: Heavy Dependence on Few Key Customers - TipRanks
(DAWN) Proactive Strategies - Stock Traders Daily
Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Earnings Results, Beats Estimates By $0.58 EPS - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Earnings Beat - MarketBeat
Pre-Market Trading Boosts Day One (DAWN) Amid High OJEMDA Demand - Stocks Telegraph
Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Buy" Rating at HC Wainwright - MarketBeat
ChromaDex Q3 2024 Earnings Preview - MSN
Day One Biopharmaceuticals, Inc. (DAWN) Surpasses Q3 Earnings and Revenue Estimates - MSN
Day One Biopharmaceuticals Reports Strong Q3 Growth - TipRanks
Day One Biopharmaceuticals earnings beat by $0.99, revenue topped estimates - Investing.com UK
DAWNDay One Biopharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress - The Manila Times
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap UpStill a Buy? - MarketBeat
Day One Biopharma shares retain overweight rating on ojemda drug usage - Investing.com UK
Day One Biopharmaceuticals (DAWN) to Release Earnings on Wednesday - MarketBeat
Global Cancer Antibody Drug Conjugates Market Size Forecast 2030 - GlobeNewswire Inc.
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 140.71%: Read This Before Placing a Bet - Yahoo Finance
DAWN Q3 EPS Estimate Boosted by Capital One Financial - MarketBeat
How To Trade (DAWN) - Stock Traders Daily
Did Day One Biopharmaceuticals Inc (DAWN) perform well in the last session? - US Post News
Low Grade Glioma Market to Rise by 2034 | Day One - openPR
Day One Biopharmaceuticals Inc (DAWN) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):